Site Munich

Brain diseases such as Alzheimer’s, Parkinson’s, and frontotemporal dementia have one thing in common despite different symptoms: The nerve cells atrophy and die. With this in mind, the DZNE site in Munich is researching the mechanisms of nerve-damaging processes in order to pave the way for new approaches in prevention, diagnosis, and treatment. To this end, the scientists are investigating a variety of phenomena such as inflammatory processes in the brain, circulatory disorders, and disease processes that are fatally triggered by the body’s own proteins.

Through human clinical studies, the Munich-based experts are conducting research to improve the early detection of dementia and movement disorders and to develop new therapeutic measures. This includes the search for “biomarkers,” which are biological parameters (such as specific measured values in the blood or cerebrospinal fluid) that help to detect a disease and assess its future progression. Clinical research in Munich also has a special focus in addition to these efforts; namely, the rare, hereditary form of Alzheimer’s disease.